安全信息
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - rat
DOSE/DURATION : 1092 mg/kg/1Y-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria
Sense Organs and Special Senses (Ear) - effect, not otherwise specified
REFERENCE :
NCITR* National Cancer Institute Carcinogenesis Technical Report Series.
(Bethesda, MD) No.0-205. For publisher information, see NTPTR*.
Volume(issue)/page/year: NCI-TR-57,1978
TYPE OF TEST : TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 175 mg/kg/8W-I
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria
Lungs, Thorax, or Respiration - tumors
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut
Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year:
33,3069,1973
RTECS | UP0175000 |
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Oral
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 467 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - conjunctive irritation
Behavioral - tremor
Gastrointestinal - hypermotility, diarrhea
REFERENCE :
NCICP* Progress Report Submitted to the National Cancer Institute by Charles
Pfizer & Co. Volume(issue)/page/year: -,522,1969
TYPE OF TEST : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE : Intravenous
SPECIES OBSERVED : Mammal - dog
DOSE/DURATION : 142 mg/kg
TOXIC EFFECTS :
Behavioral - food intake (animal)
Lungs, Thorax, or Respiration - other changes
Endocrine - hyperglycemia
REFERENCE :
CCYPBY Cancer Chemotherapy Reports, Part 3. (Washington, DC) V.1-6,
1968-75. For publisher information, see CTRRDO. Volume(issue)/page/year:
4,41,1973
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE : Intraperitoneal
SPECIES OBSERVED : Rodent - mouse
DOSE/DURATION : 354 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - conjunctive irritation
Behavioral - tremor
Gastrointestinal - hypermotility, diarrhea
REFERENCE :
NCICP* Progress Report Submitted to the National Cancer Institute by Charles
Pfizer & Co. Volume(issue)/page/year: -,522,1969